首頁 > 市場調查報告書 > 製藥

生物製劑

肽類藥物偶聯物市場規模、佔有率和成長分析：按連接子類型、有效載荷類型、適應症、研發階段、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2048614

肽類藥物偶聯物市場規模、佔有率和成長分析：按連接子類型、有效載荷類型、適應症、研發階段、最終用戶和地區分類－2026-2033年產業預測

Peptide Drug Conjugates Market Size, Share, and Growth Analysis, By Linker Type (Cleavable Linkers, Non-Cleavable Linkers), By Payload Type (Cytotoxins, Radionuclides), By Indication, By Stage, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年05月19日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球胜肽類藥物偶聯物 (PDC) 市場價值為 25.2 億美元，預計到 2025 年將成長至 28.9 億美元，到 2033 年將成長至 88.5 億美元，在預測期（2026-2033 年）內複合年成長率為 14.82%。

肽-藥物偶聯物（PDC）市場預計將迎來顯著成長，這主要得益於胜肽工程和連接子化學技術的進步，這些技術能夠提高細胞毒性藥物的標靶遞送效率。這些合成胜肽與強效治療有效載荷相結合，其療效將優於傳統生物製藥，尤其是在治療以異質性和低藥物滲透性著稱的固態腫瘤。該領域已從傳統的標靶遞送方法發展而來，融合了抗體藥物複合體（ADC）的經驗，並透過合成胜肽的基因表現改進了生產技術。這項技術進步促使製藥公司和創業投資加大投資，並催生了明確的監管路徑，以降低治療藥物開發的風險。因此，生物技術領域的合作以及生產能力的提升將加速臨床試驗，累積證據，創造商業性機會，並擴大全球PDC市場。

全球胜肽類藥物偶聯物市場的成長要素

全球胜肽-藥物偶聯物市場正受到配體選擇、胜肽與細胞毒性物質偶聯連接子設計改進以及應用於胜肽的創新工程技術的顯著推動。這些技術進步使得細胞毒性藥物能夠直接靶向遞送至病灶部位，從而最大限度地減少脫靶效應並提高治療效果。這項進展拓展了目標細胞和疾病的範圍，提高了篩選有前景的候選藥物的效率，並增加了臨床試驗的成功率。此外，在投資增加和產學研合作的推動下，臨床試驗環境的日益成熟，正在加速新型肽基藥物偶聯物的開發，並強化其在現代治療策略中的作用。

全球胜肽類藥物偶聯物市場的限制因素

由於需要複雜的合成路線、先進的結合化學以及嚴格的純化和穩定性評估流程，胜肽-藥物偶聯物的生產面臨許多挑戰。這些複雜性延長了研發週期，並對缺乏胜肽處理或連接子化學專業知識的製造商構成了挑戰。因此，能夠有效地生產臨床級產品的機構相對較少，這引發了人們對批次間一致性和監管標準合規性的擔憂。除了生產過程中固有的風險外，對專業設施和先進技術的需求也會阻礙研發管線的進展，並阻礙小規模的研發公司進入這個競爭激烈的市場。

全球胜肽類藥物偶聯物市場趨勢

全球胜肽類藥物偶聯物市場正呈現出向組織標靶遞送系統發展的顯著趨勢，這主要得益於胜肽標靶選擇和受體標靶配體技術的進步。這種對精準醫療的關注，透過最大化治療指數並最小化全身暴露，從而提高治療效果。隨著標靶特異性的提高，患者安全性也隨之提升，這使得聯合治療方法成為可能，並有助於基於生物標記的患者篩選。製藥公司與藥物研發專家之間的合作，正為針對特定疾病微環境和細胞表面標誌物客製開發偶聯物鋪路。這種策略方法不僅拓展了潛在適應症，也加速了臨床開發，使胜肽類藥物偶聯物成為現代標標靶治療和診斷的基石。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Novartis AG（Lutathera）
Advanced Accelerator Applications
Ipsen Biopharmaceuticals
Molecular Templates
Creative Biolabs
Bicycle Therapeutics
PeptiDream Inc.
CytomX Therapeutics
Pfenex Inc.
RayzeBio（BMS）
Lantheus Holdings
Fusion Pharmaceuticals
POINT Biopharma
RadioMedix
Clarity Pharmaceuticals

結論與建議

簡介目錄

Product Code: SQMIG35H2479

Global Peptide Drug Conjugates Market size was valued at USD 2.52 Billion in 2024 and is poised to grow from USD 2.89 Billion in 2025 to USD 8.85 Billion by 2033, growing at a CAGR of 14.82% during the forecast period (2026-2033).

The peptide-drug conjugates (PDCs) market is poised for significant growth, driven by advancements in peptide engineering and linker chemistry that enhance the targeted delivery of cytotoxic drugs. These synthetically derived peptides, combined with potent therapeutic payloads, outperform traditional biologics, particularly against solid tumors known for their heterogeneity and poor treatment penetration. The sector has progressed from earlier targeted delivery methods, incorporating insights from antibody-drug conjugates, and improving the genetic production of synthetic peptides. This technological evolution prompts increased investment from pharmaceutical entities and venture capitalists, presenting clearer regulatory pathways that mitigate risks in therapy development. Consequently, partnerships within the biotech sphere and enhanced manufacturing capabilities will promote clinical trials and generate evidence, fostering commercial opportunities and expanding the global PDC market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Peptide Drug Conjugates market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Peptide Drug Conjugates Market Segments Analysis

Global peptide drug conjugates market is segmented by linker type, payload type, indication, stage, end-user and region. Based on linker type, the market is segmented into cleavable linkers and non-cleavable linkers. Based on payload type, the market is segmented into cytotoxins, radionuclides and immunostimulators. Based on indication, the market is segmented into oncology, autoimmune diseases and metabolic disorders. Based on stage, the market is segmented into pre-clinical, clinical and approved. Based on end-user, the market is segmented into pharma companies, biotech companies and CROs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Peptide Drug Conjugates Market

The Global Peptide Drug Conjugates market is significantly driven by advancements in ligand selection, enhanced linker designs connecting peptides to cytotoxins, and innovative engineering methods applied to peptides. These technological advancements enable targeted delivery of cytotoxic drugs directly to disease sites, minimizing off-target effects and boosting treatment efficacy. This progress broadens the spectrum of cell and disease types that can be targeted, facilitating a more efficient process for identifying promising drug candidates while increasing the likelihood of success in clinical trials. Furthermore, the maturation of the clinical trial landscape, fueled by increased investment and collaboration between academia and industry, promotes the development of new peptide-based drug conjugates, enhancing their role in modern treatment strategies.

Restraints in the Global Peptide Drug Conjugates Market

The manufacturing of peptide drug conjugates faces significant challenges due to the intricate synthesis routes, complex conjugation chemistries, and the need for rigorous purification and stability processes. These complexities extend the development timeline and present challenges for manufacturers lacking expertise in peptide handling or linker chemistries. Consequently, there are relatively few organizations equipped to produce clinical-grade materials efficiently, leading to concerns regarding batch consistency and adherence to regulatory standards. The inherent manufacturing risks, coupled with the requirement for specialized facilities and advanced knowledge, can impede progress in the pipeline and discourage smaller developers from entering this competitive market.

Market Trends of the Global Peptide Drug Conjugates Market

The Global Peptide Drug Conjugates market is witnessing a significant trend toward tissue-targeted delivery systems, driven by advancements in peptide target selection and receptor-targeted ligands. This focus on precision medicine enhances therapy efficacy by maximizing the therapeutic index while minimizing systemic exposure. As target specificity improves, safety profiles for patients rise, enabling the combination of therapeutic regimens and facilitating biomarker-driven patient selection. Collaborative efforts between pharmaceutical companies and drug discovery experts are paving the way for the tailored development of conjugates that address unique microenvironments and cell surface markers of diseases. This strategic approach not only expands potential indications but also accelerates clinical development, positioning peptide drug conjugates as a cornerstone in modern targeted therapies and diagnostics.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Peptide Drug Conjugates Market Size by Linker Type & CAGR (2026-2033)

Market Overview
Cleavable Linkers
Non-Cleavable Linkers

Global Peptide Drug Conjugates Market Size by Payload Type & CAGR (2026-2033)

Market Overview
Cytotoxins
Radionuclides
Immunostimulators

Global Peptide Drug Conjugates Market Size by Indication & CAGR (2026-2033)

Market Overview
Oncology
Autoimmune Diseases
Metabolic Disorders

Global Peptide Drug Conjugates Market Size by Stage & CAGR (2026-2033)

Market Overview
Pre-Clinical
Clinical
Approved

Global Peptide Drug Conjugates Market Size by End-User & CAGR (2026-2033)

Market Overview
Pharma Companies
Biotech Companies
CROs

Global Peptide Drug Conjugates Market Size & CAGR (2026-2033)

North America (Linker Type, Payload Type, Indication, Stage, End-User)
- US
- Canada
Europe (Linker Type, Payload Type, Indication, Stage, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Linker Type, Payload Type, Indication, Stage, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Linker Type, Payload Type, Indication, Stage, End-User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Linker Type, Payload Type, Indication, Stage, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novartis AG (Lutathera)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced Accelerator Applications
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Biopharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Molecular Templates
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Creative Biolabs
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bicycle Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PeptiDream Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CytomX Therapeutics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfenex Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RayzeBio (BMS)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lantheus Holdings
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fusion Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
POINT Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
RadioMedix
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clarity Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments